Mesoblast Limited (AU:MSB) has released an update.
JPMorgan Chase & Co. and its affiliates have become substantial holders in Mesoblast Limited, acquiring a 6.08% voting power with over 69 million ordinary shares. This development highlights the financial giant’s strategic interest in the biotech company’s potential, signaling a noteworthy shift in shareholding dynamics for Mesoblast investors.
For further insights into AU:MSB stock, check out TipRanks’ Stock Analysis page.